THC Biomed Intl Ltd.
THCBF · OTC
4/30/2023 | 1/31/2023 | 10/31/2022 | 7/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.31 | -0.01 | 0.05 | -0.00 |
| FCF Yield | 0.50% | -2.03% | -4.45% | -4.71% |
| EV / EBITDA | -17.21 | -12.80 | -890.27 | -12.87 |
| Quality | ||||
| ROIC | -10.74% | -10.06% | -2.48% | -13.84% |
| Gross Margin | -77.78% | -45.73% | 27.09% | -66.71% |
| Cash Conversion Ratio | -0.04 | 0.04 | 0.70 | 0.19 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.61% | -4.44% | -8.56% | -7.19% |
| Free Cash Flow Growth | 135.55% | 53.58% | 45.91% | 32.86% |
| Safety | ||||
| Net Debt / EBITDA | -4.07 | -3.98 | -251.27 | -1.77 |
| Interest Coverage | -4.96 | -4.73 | -1.98 | -6.59 |
| Efficiency | ||||
| Inventory Turnover | 0.33 | 0.43 | 0.15 | 0.54 |
| Cash Conversion Cycle | 154.27 | 161.33 | 445.18 | 147.48 |